Articles On Respiri (ASX:RSH)
Title | Source | Codes | Date |
---|---|---|---|
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | RSH | 2 weeks ago |
ASX October Winners: The 50 best stocks in weaker month for markets
The S&P/ASX 200 fell 1.3% in October with small cap companies outperforming S&P Dow Jones Indices said financials led the gains in October and is up 30% YTD Ovanti rose 525% in October after appointment of former Zip US CFO Simon K... |
Stockhead | RSH | 2 weeks ago |
Respiri increases patient enrolments, revenue and conversion rates with streamlined onboarding system
Healthcare company Respiri (ASX: RSH) delivered strong growth in patient enrolments during the three months to the end of September across its chronic care management, remote patient monitoring, principal care management and transitional ca... |
SmallCaps | RSH | 4 weeks ago |
Health Check: Approval clock ticks as FDA accepts Telix’s brain diagnostic marketing application
Telix Pharmaceuticals’ brain cancer diagnostic could leapfrog over its kidney cancer assay to be its second commercialised product Rhythm Biosciences still hopes to flush the bowel cancer ‘poo test’ into history Today’s quarterly reports s... |
Stockhead | RSH | 4 weeks ago |
Closing Bell: ASX hits record, Nanoveu doubles on AI news, Tyro drops 10pc on new debit card proposal
ASX 200 hits record highs fuelled by Wall Street rally Tech and iron ore stocks lead gains Tyro sinks after government proposes new rules on debit surcharge The ASX 200 index hit record highs on Tuesday after rising by 0.9%, eclipsin... |
Stockhead | RSH | 1 month ago |
Health Check: Thirsty Chimeric goes to the well for funding top-up
Cancer drug developer Chimeric Therapeutics eyes minimum $5 million raising ‘The next Telix’, Clarity gets FDA go-ahead for prostate cancer trial LTR Pharma fleshes out erectile dysfunction trial results Cancer cell therapy house Chimer... |
Stockhead | RSH | 1 month ago |
Closing Bell: Arcadium holders cash in, Oil rallies as Milton hits, and GYG keeps momentum going
ASX gains as energy and mining stocks rally Arcadium Lithium surges after Rio acquisition, while GYG reports strong Q1 Hurricane Milton lands and pushes oil prices higher The ASX gained ground by 0.3% on Thursday and neared its recor... |
Stockhead | RSH | 1 month ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | RSH | 1 month ago |
Respiri partners with Hawaiian care facilities in remote patient monitoring deal
Medical technology specialist Respiri (ASX: RSH) has once again displayed the diversity of its business offering by reaching agreements to provide remote nursing support to care facilities in Hawaii. The company has entered into two individ... |
SmallCaps | RSH | 1 month ago |
Alive and Kicking: Respiri promises breath of life to bottom line after inking US distribution deal
‘Wheezo’ maker Respiri says a new US deal will help to propel the company to cash-flow break even by the end of the year Immutep reports further promising data from its head neck and shoulder cancer program Oncosil Medical targets the diff... |
Stockhead | RSH | 2 months ago |
Closing Bell: ASX steady as coal play Coronado sinks 16pc; NextDC rides on data centre boom
ASX up on Thursday, tech stocks rise boosted by NextDC Wodside Energy drops due to downgrade and oil price fall Iron Ore and coal slide, and Coronado sinks on production and cost issues After a rough session on Wednesday, the ASX saw a... |
Stockhead | RSH | 2 months ago |
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment The ASX Healthcare Index (AS... |
Stockhead | RSH | 2 months ago |
Air supply: The ASX medtechs tackling respiratory illnesses
ANDHealth says the Covid-19 pandemic triggered far-reaching changes to Australia’s health system and how we manage respiratory illnesses Lumos Diagnostics has developed FebriDx to helps doctors quickly differentiate a viral from bacterial... |
Stockhead | RSH | 3 months ago |
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July The S&P/ASX 200 Health Care index [XHJ]... |
Stockhead | RSH | 3 months ago |
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month In a major blow for... |
Stockhead | RSH | 3 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | RSH | 4 months ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | RSH | 5 months ago |
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners
Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month The phrase ‘you are what you eat’ was coined almost a c... |
Stockhead | RSH | 6 months ago |
Closing Bell: ASX rides high as gold, silver, copper, and iron ore surge; Nuix jumps 25pc
ASX 200’s rally was driven mainly by gold/silver and iron ore stocks Gold prices hit record high as China continues to buy bullion Asian markets rose due to high commodity prices and new stimulus measures The ASX 200 index rose by +0.... |
Stockhead | RSH | 6 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | RSH | 6 months ago |
Adherium’s focus on US market could pay off big time for its novel asthma device
Asthma affects hundreds of millions of people globally While inhalers are effective, people are not taking them correctly Adherium addresses this problem, as we reached out to CEO Paul Mastoridis It’s one of the most common chronic dise... |
Stockhead | RSH | 6 months ago |
Market Highlights: ASX to lift on the back of Nasdaq rally; and 5 small caps to watch today
ASX to lift on the back of Nasdaq rally US stocks rose on Friday as big techs reported solid results The US PCE Index however came in stronger than expected Aussie shares are poised to open higher on Monday on the back of a Nasdaq ra... |
Stockhead | RSH | 6 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | RSH | 6 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | RSH | 8 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | RSH | 8 months ago |
Closing Bell: ASX traders happy to take the profit after surprise CPI windfall
The ASX benchmark has ended Wednesday higher after positive inflation data 7 of 11 sectors in the green, IT ahead by circa +2pc Small caps led by Euro Manganese The local market has trimmed the CPI fat of this morning’s gains, after the... |
Stockhead | RSH | 11 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | RSH | 1 year ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | RSH | 1 year ago |
Unith posts 25pc Q1 revenue growth ahead of AI digital human service “soft launch”
Digital human developer Unith (ASX:UNT) posts 25 per cent lift in revenue for Q1 FY24 At the quarter’s end, the company held $2.7 in cash on hand Unith inked several new contracts over the quarter across the healthcare, e-lottery, and... |
themarketherald.com.au | RSH | 1 year ago |
Respiri (ASX:RSH) – Webinar Presentation
Marjan Mikel – CEO – Respiri (ASX:RSH) offers the only remote patient monitoring program with remote wheeze detection for respiratory disorders as well as a broad number of serious chronic conditions. |
ShareCafe | RSH | 1 year ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | RSH | 1 year ago |
Research To Download: Actinogen, De.mem, Quantm, Spartan, & Others
Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=7D2FBF3D-0297-B05B-8F498AF62BD096F8 –AFT Pharmaceuticals ((AFP)) by Edi... |
FNArena | RSH | 1 year ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | RSH | 1 year ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | RSH | 1 year ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | RSH | 1 year ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | RSH | 1 year ago |
CLOSING BELL: Local markets close 0.24pc lower, The Star gets a lifeline and Allkem neighbour Rubix flies high
The benchmark has sagged to -0.24% to close out the week with a world-weary sigh. Falling crude prices hobbled the Energy sector, dragging it 1.93% lower. Small caps winner Rubix Resources is feeling some neighbourly love, thanks to Allk... |
Stockhead | RSH | 1 year ago |
CLOSING BELL: CBA makes bank from rising rates, then issues a warning about mortgage arrears
Local markets have pedalled furiously since lunch to bring the benchmark to +0.35%. CBA posts record $10.2 billion profit off the back of ever-increasing interest rates. Small capper Perpetual stuns with a 50% spike after buying up land in... |
Stockhead | RSH | 1 year ago |
CLOSING BELL: Late rally sees the ASX almost emerge from day-long lurk in the bog
A late surge from InfoTech pushed the benchmark to close at +0.07% InfoTech out front on +1.75%, ahead of Energy and Consumer Discretionary Huge news from Azure helped neighbour Errawarra into top spot for Small Caps It’s the end of the... |
Stockhead | RSH | 1 year ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | RSH | 1 year ago |
Research To Download: Amaero, Carly, Freelancer, Sensen Networks, Wrkr, And More
Research reports on ASX-listed companies, to download in full. **** -Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=04E6FD35-F066-D52A-FF94AEB002399CD2 -Carly Holdings ((C... |
FNArena | RSH | 1 year ago |
What to know about the TechKnow Invest Roadshow
Whilst the prevalence of Artificial intelligence has boosted the US-tech sector, with the likes of Nvidia and C3.ai seeing their share prices increase by 219% and 265% respectively since the start of the year, Down Under, tech stock valuati... |
ShareCafe | RSH | 1 year ago |
Research To Download: Cannindah, Comms, Hot Chili, Kinatico & Lithium Power
Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=628D02C0-B9D8-EA23-2DB35CB4E58A7CBE –AFT Pharmaceuticals ((AFT)) by Edi... |
FNArena | RSH | 1 year ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | RSH | 1 year ago |
Respiri (ASX:RSH) – Webinar Presentation
ShareCafeRespiri (ASX:RSH) – Webinar Presentation Marjan Mikel, CEO and Brian Leedman, Non-Executive Director – Respiri Limited (ASX:RSH) is leading the way in the development of innovative eHealth solutions that aim to improve the managem... |
ShareCafe | RSH | 1 year ago |
Research To Download: Kinatico, Qantm, State Gas & Vection Technologies
Research reports on ASX-listed companies, to download in full. **** –AFT Pharmaceuticals ((AFP)) – Edison Research: https://www.fnarena.com/index.php/download-article/?n=5CCC26AF-A670-63C8-370E356F819BE3C4 –Barrow Handley Global Share Fund... |
FNArena | RSH | 1 year ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | RSH | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | RSH | 1 year ago |
CLOSING BELL: Mega gold merger outweighs bankers’ ex-div dive, leaving the ASX up 0.1%
After a feeble start, the benchmark has rallied to close at +0.1% Newcrest and Newmont shake hands on Australia’s biggest goldie takeover Westar Resources shines bright with a 47% price hike As far as days on the ASX go, that definitely... |
Stockhead | RSH | 1 year ago |
Research To Download: Actinogen, Amaero, Pointerra, Respiri, Ricegrowers, Schrole, And More
Research reports on ASX-listed companies, to download in full. –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=F863639F-EF2C-E5CB-37099553DD439B58 –AFT Pharmaceuticals ((AFP)) by Edison R... |
FNArena | RSH | 1 year ago |